The Bone Resorption Assessment is a simple urinary test that provides an accurate assessment of the rate of bone turnover in an individual. The Bone Resorption Assessment allows the practitioner to identify those more likely to develop osteoporosis, to intervene before significant loss has occurred, and to monitor the efficacy of treatment regimens. It examines pyridinium crosslinks and deoxypyridinoline and is useful in identifying current rate of bone loss, lytic bone disease, and efficacy of bone support therapies.
Hormone Testing and Osteoporosis:
- Osteoporosis leads to 1.5 million fractures per year
- Osteoporosis affects more than 50% of healthy American women aged 30-40 who are likely to develop vertebral fractures as they age
- Hormone testing is an important component to identify individuals currently losing bone at an accelerated rate so that effective treatment can begin before significant bone loss has occurred
Measuring Bone Resorption
Pyridinium crosslinks are stabilizers of collagen molecules. Bone collagen contains bothpyridinoline (PYD), which is reflective of collagen loss of all types, and its component deoxypyridinoline (DPD), which specifically reflects bone collagen. Presence in the urine of higher than normal amounts of PYD and DPD indicate a rapid rate of bone loss.
Crosslink excretion is greatly increased in patients with osteoporosis, as well as in a number of other conditions. These include Paget’s disease, primaryhyperparathyroidism, and osteomalacia. Measurement of PYD crosslinks has also proven useful in arthritic diseases, connective tissue disorders, cancer metastasis, and alcoholic bone disease.
Test Type: Urine Test